Cercare il medicinale per il nome

Sodium Edecrin e Ototossicità

Risultato del controllo d'interazione tra il farmaco Sodium Edecrin e la malattia Ototossicità su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Sodium Edecrin <> Ototossicità

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Tinnito e perdita dell'udito, sia reversibile e permanente, sono stati riportati con l'uso di diuretici. Ototossici effetti sono stati generalmente associati con rapida per via endovenosa o intramuscolare, grave insufficienza renale, insolitamente alti dosaggi (cioè più volte il solito raccomandato dosi), e/o l'uso concomitante di altri agenti ototossici. La terapia con diuretici deve essere somministrato con cautela in pazienti con preesistente vestibolare e/o uditiva deterioramento, in quanto può ritardare il riconoscimento o confondere la diagnosi di un indotta da farmaci ototossici effetto. Ad alte dosi per via parenterale, la terapia deve essere somministrata come controllata di infusione.

Fonte

Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973): 325-36
Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975): 166-8,180
Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979): 309-19
Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970): 427-8
Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966): 715-7
Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971): 1156
Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995): 1771-80
Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978): 791-800
Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988): 518-20
Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969): 673-4
Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980): 702
Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970): 159
Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971): 359-63
David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971): 1328
Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975): 94-101
Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970): 1413
Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976): 1065-86
Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995): 121-42
Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976): 561-70
"Product Information. Bumex (bumetanide)." Roche Laboratories, Nutley, NJ.
Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971): 795-8
"Product Information. Edecrin (ethacrynic acid)." Merck & Co, Inc, West Point, PA.
Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970): 1052
Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970): 761
Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971): 113
Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973): 831-4
Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970): 954-65
"Product Information. Demedex (torsemide)." Boehringer Mannheim, Gaithersburg, MD.
David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971): 1328-9
"Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.
Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970): 159
Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995): 1771-80
Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969): 77-9
Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969): 152-5
Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981): 399-414
Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993): 829-44
Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971): 1152
Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973): 515-6
Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968): 2119
Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995): 396-402